Identification of natural bioactive compounds able to increase GLYI activity and/or expression (GLYI inducers), thus contributing to protection against MG accumulation and dicarbonyl stress, is receiving great interest for their very promising value as novel pharmaceuticals in prevention and treatment of type 2 diabetes, vascular complications of diabetes, and other AGE-promoted human disorders [12,40]. The gene discussed is GLO1; the disease is diabetes mellitus.